about
COPD exacerbation: lost in translationIdiopathic pulmonary hemosiderosis in adults: a case report and review of the literatureCommunity acquired bacterial pneumoniaInhibition and role of let-7d in idiopathic pulmonary fibrosisApplication of microarray technology in pulmonary diseasesUse of interrupter technique in assessment of bronchial responsiveness in normal subjectsThe predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcomeTh1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosisSerum biomarkers in acute respiratory distress syndrome an ailing prognosticatorAn official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumoniasA 10-year aerobiological study (1994-2003) in the Mediterranean island of Crete, Greece: trees, aerobiologic data, and botanical and clinical correlations.Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma."Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role?Current and future therapeutic approaches in idiopathic pulmonary fibrosis.Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema.Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?Comparative analysis of induced sputum and bronchoalveolar lavage fluid (BALF) profile in asbestos exposed workersPulmonary lymphangioleiomyomatosis associated with retroperitoneal lymphangioleiomyomasγ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer.Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis.Role of streptokinase in the treatment of acute loculated parapneumonic pleural effusions and empyema.Intrapleural fibrinolytic therapy for pleural infection.Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus.Update on pleural disease: introduction.Post-intubation pulmonary embolism and tracheal stenosis: a case report and review of the literature.Current pharmacological treatment of pulmonary arterial hypertension.Pleural effusions in critically ill patients.Apoptosis in lung injury and fibrosis.New developments in the management of COPD: clinical utility of indacaterol 75 μg.Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube.Acute fibrinous and organising pneumonia: a case report and review of the literature.γ -H2AX: A Novel Prognostic Marker in a Prognosis Prediction Model of Patients with Early Operable Non-Small Cell Lung Cancer.Adult respiratory distress syndrome due to Chlamydia pneumoniae in a young adult.Stem cell therapy in pulmonary fibrosis.Mechanisms of pleural involvement in orphan diseases.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Current evidence for the management of paediatric parapneumonic effusions.The pathogenesis of pulmonary fibrosis: a moving target.Regenerative medicine and stem cells: prometheus revisited.
P50
Q21257182-B7170987-277B-4E10-B39B-A8D3730B219DQ21296681-DB642E79-CF06-41C5-AA7C-46C59136DE0BQ22241379-B250874B-9D67-4D12-A157-76ECEC695BE9Q24599153-BC66DB59-1F8A-42C0-AEE2-0DF27E55A1EEQ24799102-CE8810ED-67F1-4833-8B4C-96CA0B4A9247Q24799684-8FC842AC-2E3C-4E1C-9C1A-E440E43F56C9Q24802498-053AC988-5725-4E5C-8EAC-C80F20D8E271Q24810989-9ABFA737-BAF5-4D7C-9AF3-E498B7F86E5BQ24815239-9E6BC8E8-0FCD-40F6-B9B4-DC803AA3FAACQ28298430-3A02CBCE-F8B8-4EAA-BC33-35D4D05A5A30Q31070032-C74746D8-8292-4DA0-8991-86CAFC970DABQ33381328-CF56C2DA-AECD-4E17-BBB1-2E8BAE524A3FQ33693227-0326B426-1A95-4BA6-A1C4-6C46FE2CA979Q33984737-02463C4F-7C80-40C0-9616-0D8BF49CAF1DQ33990489-5267C711-11C9-4BC9-A9CE-63BF13682BA1Q34734509-77965F0C-0277-41CE-B605-10959EDD2654Q34882979-24180E59-5C31-4B62-8DF1-712416701521Q35206336-FC3AB3E8-B118-4853-9582-D754C11E2740Q35685902-46B938F9-A681-4142-8896-588FD1D36998Q36409165-2A68BED5-A7A6-45A3-BB7D-9D163F3BD463Q36413496-304E5881-16B9-4EE8-82B5-7F1F76B904D1Q36574815-1DAD6E9A-3EAF-4CB8-B0A8-91713311D7DAQ36627482-B3978F9C-A5DB-47B2-AE94-835D36DB648FQ36818173-53D4EF2C-AD3C-4744-A612-D4FE3CAD15F1Q37054044-6D64C587-F5AB-424F-AEF3-0DE9442343BCQ37200021-D8D10D8B-AC7D-43B9-B514-4B2E3D03F851Q37239197-D22914B6-F577-4073-8C29-E78BE7F22402Q37282194-3E4DF9A0-BB69-45D9-AAAB-515D2AE8A5C2Q37337820-44D4BDC1-71E6-4FAB-AA3C-3028CF1F3F64Q37390883-E98CFD20-F4D4-4900-8B56-CE09FA0BCE5BQ37391291-96AA20E2-9A7E-433B-8D27-73DA94BF1381Q37437467-2FFE161F-B817-4503-9F96-EB2784B9092FQ37543259-FA475FDC-E6C4-48DF-8DE3-4FE75CFD0CF6Q37885000-8ED42157-3BF7-404D-A013-49F201F74EFAQ37890845-12DB4BD0-6D95-46E5-BBC0-A5EE56964D49Q37976241-F3B295FC-7F15-416D-A62D-7FBAD1C76CB5Q37999465-FC0448E3-0880-416E-A65B-66644AC89E33Q38002550-A2927BA4-1E32-4E94-8CA8-EFCA0A0938BBQ38055722-23EEA78F-B6B9-43B4-AF7F-D70AAA116FF8Q38064670-6DB50192-E0A3-4D1A-B0F3-55D0611A36B1
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-0685-0765
@en
name
Demosthenes Bouros
@ast
Demosthenes Bouros
@en
Demosthenes Bouros
@es
Demosthenes Bouros
@nl
type
label
Demosthenes Bouros
@ast
Demosthenes Bouros
@en
Demosthenes Bouros
@es
Demosthenes Bouros
@nl
prefLabel
Demosthenes Bouros
@ast
Demosthenes Bouros
@en
Demosthenes Bouros
@es
Demosthenes Bouros
@nl
P106
P1153
7005145349
P31
P496
0000-0002-0685-0765